Credit Suisse Group Reiterates “€110.00” Price Target for Merck KGaA (MRK)
Credit Suisse Group set a €110.00 ($127.91) price objective on Merck KGaA (FRA:MRK) in a research note issued to investors on Wednesday, Borsen Zeitung reports. The brokerage currently has a buy rating on the healthcare company’s stock.
A number of other research firms also recently weighed in on MRK. Sanford C. Bernstein set a €105.00 ($122.09) target price on shares of Merck KGaA and gave the company a buy rating in a research report on Monday, April 8th. Barclays set a €82.00 ($95.35) target price on shares of Merck KGaA and gave the company a sell rating in a research report on Monday, April 8th. Warburg Research set a €103.00 ($119.77) price target on shares of Merck KGaA and gave the company a neutral rating in a research note on Tuesday, April 9th. UBS Group set a €108.00 ($125.58) price target on shares of Merck KGaA and gave the company a neutral rating in a research note on Monday, April 1st. Finally, DZ Bank reiterated a neutral rating on shares of Merck KGaA in a research note on Tuesday, April 2nd. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of Hold and a consensus price target of €101.05 ($117.50).
Merck KGaA stock traded up €0.66 ($0.77) during mid-day trading on Wednesday, reaching €91.76 ($106.70). The company’s stock had a trading volume of 366,117 shares. Merck KGaA has a 12 month low of €76.60 ($89.07) and a 12 month high of €115.00 ($133.72).
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Further Reading: What is an overbought condition?
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.